Literature DB >> 11387301

Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome.

S Kirchengast1, J Huber.   

Abstract

Body composition, fat distribution and bone mineral density were examined in lean women suffering from polycystic ovary syndrome (PCOS) and compared with body composition and fat distribution characteristics of weight-matched lean controls. Ten women with PCOS and a body mass index (BMI) below 25.00 (kg/m(2)) and 10 healthy women with a BMI below 25.00 (kg/m(2)) matched for age and weight and BMI as controls were enrolled in this study. Body composition and bone density were measured by dual-energy- x-ray-absorptiometry and fat distribution patterns were calculated. Although matched for age, weight and BMI, lean PCOS patients showed a significantly higher amount of body fat and lower amount of lean body mass than the controls. The majority of PCOS patients showed an intermediate or android kind of fat distribution. Only 30% of the lean PCOS patients corresponded to the definition of gynoid fat distribution while this was true of all lean controls.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11387301     DOI: 10.1093/humrep/16.6.1255

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  53 in total

1.  Evidence of proatherogenic inflammation in polycystic ovary syndrome.

Authors:  Frank González; Neal S Rote; Judi Minium; John P Kirwan
Journal:  Metabolism       Date:  2009-07       Impact factor: 8.694

2.  Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndrome.

Authors:  Elisabeth Wehr; Reinhard Möller; Renate Horejsi; Albrecht Giuliani; Daisy Kopera; Natascha Schweighofer; Andrea Groselj-Strele; Thomas R Pieber; Barbara Obermayer-Pietsch
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 3.  The metabolic syndrome in polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

4.  Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women.

Authors:  Daniel A Dumesic; Alin L Akopians; Vanessa K Madrigal; Emmanuel Ramirez; Daniel J Margolis; Manoj K Sarma; Albert M Thomas; Tristan R Grogan; Rasha Haykal; Tery A Schooler; Bette L Okeya; David H Abbott; Gregorio D Chazenbalk
Journal:  J Clin Endocrinol Metab       Date:  2016-08-29       Impact factor: 5.958

5.  Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome.

Authors:  Uche Ezeh; Marita Pall; Ruchi Mathur; Ricardo Azziz
Journal:  Hum Reprod       Date:  2014-05-09       Impact factor: 6.918

6.  Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndrome.

Authors:  C M Bruns; S T Baum; R J Colman; D A Dumesic; J R Eisner; M D Jensen; L D Whigham; D H Abbott
Journal:  Int J Obes (Lond)       Date:  2007-05-01       Impact factor: 5.095

7.  Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome.

Authors:  Brooke Rossi; Sara Sukalich; Jennifer Droz; Adam Griffin; Stephen Cook; Aaron Blumkin; David S Guzick; Kathleen M Hoeger
Journal:  J Clin Endocrinol Metab       Date:  2008-09-23       Impact factor: 5.958

Review 8.  Mediators of inflammation in polycystic ovary syndrome in relation to adiposity.

Authors:  Thozhukat Sathyapalan; Stephen L Atkin
Journal:  Mediators Inflamm       Date:  2010-04-08       Impact factor: 4.711

Review 9.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

10.  Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome.

Authors:  E Faloia; P Canibus; C Gatti; F Frezza; M Santangelo; G G M Garrapa; M Boscaro
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.